Reuters logo
FDA staff raise safety concerns over Sanofi MS drug Lemtrada
November 8, 2013 / 2:16 PM / 4 years ago

FDA staff raise safety concerns over Sanofi MS drug Lemtrada

Nov 8 (Reuters) - U.S. regulatory officials raised concerns about “multiple serious and potentially fatal safety issues” in patients given Sanofi’s new multiple sclerosis drug Lemtrada, raising concerns over its approval.

Shares in Sanofi fell 2 percent after the documents were posted on the FDA’s website on Friday.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below